Ono focuses on drug discovery leads that are high in certainty and globally competitive. Capitalizing on the technologies and know-how nurtured through our research history, we propel drug development in areas where we can continue to optimize our strengths and in areas where we can effectively utilize the genes we possess as our genetic assets in the field of genomic drug discovery. We are in active pursuit of the discovery and development of drugs that meet the unmet medical needs at the frontline of healthcare.

By strengthen strategic alliances globally, we endeavor to bolster our drug discovery capability, introducing breakthrough drug discovery seeds and leading-edge technologies from bio-pharmaceutical companies, academic institutions and research establishments in Europe and the US.

We are expanding our development pipeline directing our efforts toward acquiring commercialization rights to new drug candidates.

Our R&D policy is the basis of our drive to enhance our corporate social value through the continued development and commercialization of "drugs that deliver true benefit to patients." We are ready and poised to tackle the global market, armed with all our strengths.

We would like to take this opportunity to express our sincere gratitude to our customers and stockholders for your continued support. We will work toward increased confidence in the world community.